| Testosterone | Abbvie | ||
| 1% ; Testosteron gel |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
Less Than 5
|
None | ||
|
Less Than 5
|
Less Than 5
|
||
| Testosterone replacement therapy in adult males with congenital or acquired primary hypogonadism or hypogonadotropic hypogonadism. | |||
|
Yes
| |||
| Androgel | Patent 1 | Patent 2 | Patent 3 |
|---|---|---|---|
| ****** | ******* | ******* | ******* |
| ******* (***) | ******* | ******* | ******* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ****** | *** \ *** | *** **, **** | ******* | ******** | ** *** **, **** |
| ******* (***) | *** \ ** | *** **, **** | ******* | ******** | ** **** *, **** |
| Testosterone | Abbvie | ||
| 1.62% (20.25mg/1.25gm Actulation) |
Less Than $1000 mn
|
||
|
Less Than 5
|
More Than 5
|
||
|
Less Than 5
|
None | ||
|
More Than 5
|
More Than 5
|
||
| Increase testosterone in Men. | |||
|
Yes
| |||
| Androgel | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ***** | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ******* | *** \ *** | *** **, **** | ******* | ******** | ******** ** *** **, **** |
| ******* | *** \ ** | **** **, **** | ******* | ******** | ******** ** ***** **, **** |
| ***** | ** \ ** | ***** *, **** | ******* | ******** | ******** ** ***** **, **** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|